Drug intelligence / Profile preview

Ebvax

Development stage: Preclinical
Lead developer: Rational Vaccines
Modality: Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**Ebvax** is an investigational prophylactic Epstein-Barr virus vaccine developed by Grid Biosciences. It uses the company's Ferritin Vehicle platform, in which Epstein-Barr virus components are fused to self-assembling ferritin nanoparticles to present viral antigens and induce durable protective immune responses. The program is intended to prevent Epstein-Barr virus infection and potentially reduce the burden of Epstein-Barr virus-associated diseases. ([gridbiosciences.com](https://www.gridbiosciences.com/px))

Brand names: Ebvax
Other names: EBVAX

Beyond the preview

Go deeper on Ebvax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ebvax.

Explore the full profile